

Connecticut HB 6669 Disclosure
Qelbree® (Safinamide Mesylate)

Supernus Pharmaceuticals, Inc. (Supernus) provides the following information to Connecticut prescribers, as required by Connecticut House Bill 6669.

The pricing information below reflects Supernus Wholesale Acquisition Costs (“WAC”) for the Supernus product: Qelbree®. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the prices listed, depending, for example, on how the customer purchases the product, the availability of discounts, the wholesaler/distributor, or other charges.

WAC for Qelbree®

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
Qelbree® (Viloxazine)	17772-0131-30	Capsule 100 MG	\$400.14
Qelbree® (Viloxazine)	17772-0132-30	Capsule 150 MG	\$400.14
Qelbree® (Viloxazine)	17772-0133-30	Capsule 200 MG	\$400.14
Qelbree® (Viloxazine)	17772-0133-60	Capsule 200 MG	\$800.28

Generic versions of Qelbree are not currently available. Information on variation efficacy of the drug marketed to different racial and ethnic groups is currently not available.

For more information on the price disclosure requirements, please contact the Connecticut State Board of Pharmacy at:

State Board of Pharmacy
450 Columbus Blvd Hartford, CT 06103
Ph. (860) 713-6070 | Fax: (860)-706-1242 | Website: <https://portal.ct.gov/DCP/Drug-Control-Division/Commission-of-Pharmacy/The-Commission-of-Pharmacy>

Qelbree® is a registered trademark of Supernus Pharmaceuticals, Inc.
Copyright© 2026 Supernus All rights reserved.
4/7/2026